Bicara Therapeutics (BCAX) Non Operating Income (2023 - 2026)

Bicara Therapeutics (BCAX) has 4 years of Non Operating Income data on file, last reported at $4.1 million in Q1 2026.

• For the quarter ending Q1 2026, Non Operating Income fell 18.57% year-over-year to $4.1 million; the trailing twelve-month figure through Mar 2026 stood at $16.9 million (up 1.27% YoY), and the FY2025 full-year result was $17.9 million, up 22.56% from the prior year.
• Non Operating Income for Q1 2026 stood at $4.1 million, up from $3.8 million in the prior quarter.
• Across five years, Non Operating Income topped out at $5.9 million in Q4 2024 and bottomed at -$13.3 million in Q3 2023.
• The 4-year median for Non Operating Income is $3.8 million (2025), against an average of $2.2 million.
• The widest annual swing landed in 2024, when Non Operating Income jumped 368.53%; it then sank 35.41% in 2025.
• A 4-year view of Non Operating Income shows it stood at $1.3 million in 2023, then soared by 368.53% to $5.9 million in 2024, then tumbled by 35.41% to $3.8 million in 2025, then grew by 7.76% to $4.1 million in 2026.
• The last three Non Operating Income figures came in at $4.1 million (Q1 2026), $3.8 million (Q4 2025), and $4.4 million (Q3 2025), per Business Quant data.

Peer Comparison